Form 4: CEO Robert Fried Granted Niagen Bioscience Stock Options

Niagen Bioscience CEO Robert Fried was granted 503,937 employee stock options with an exercise price of $4.94, vesting annually over four years.

Summary

• Robert N. Fried, who serves as Chief Executive Officer and Director of Niagen Bioscience, Inc. (NAGE), was granted 503,937 employee stock options.
• The exercise price for these options is $4.94 per share.
• The grant date for the options was February 19, 2026.
• The options are subject to a vesting schedule where one-fourth of the shares will vest on each anniversary of the grant date, commencing February 19, 2027.
• The expiration date for these employee stock options is February 18, 2036.
• Following this transaction, Mr. Fried beneficially owns 503,937 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the grant of stock options to the CEO aligns management's long-term interests with shareholder value creation, which is a standard and often beneficial compensation practice.

Positives

• The grant of 503,937 employee stock options to CEO Robert N. Fried aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The multi-year vesting schedule, with one-fourth of shares vesting annually over four years, encourages sustained commitment and performance from the CEO.

Negatives

• No direct negatives are apparent from this routine insider compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The vesting schedule for the employee stock options indicates a future incentive structure, with one-fourth of the options becoming exercisable on each anniversary of the grant date, starting February 19, 2027, and continuing for four years.

Industry Context

StockSavvy.ai notes that the grant of employee stock options to a CEO is a common practice in executive compensation across various industries. This mechanism is designed to align the interests of top management with those of shareholders by tying a portion of their compensation to the company's stock performance. For a bioscience company like Niagen Bioscience, attracting and retaining key talent through equity incentives is crucial, especially given the long development cycles and inherent risks in the sector.

Comparison to Industry Standards

• Executive compensation packages often include equity components like stock options, particularly in growth-oriented sectors such as biotechnology and bioscience.
• While the specific number of options (503,937) and exercise price ($4.94) are company-specific, the structure of a multi-year vesting schedule (one-fourth annually) is a standard practice seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their executives, aiming to foster long-term commitment and performance.
• The exercise price being at or above the market price on the grant date is also typical for incentive stock options.

Corporate Governance

Related Party Transactions

• This filing reports an insider transaction (grant of options to the CEO), which is a form of related party dealing, but it is a standard compensation event rather than an unusual transaction.

Stakeholder Impact

• Shareholders: The option grant aims to align the CEO's financial incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• One-fourth of the granted options will vest on February 19, 2027, and annually thereafter for three more years.
• The options will remain exercisable until their expiration date of February 18, 2036.

Key Dates

Keywords

Niagen Bioscience, NAGE, Robert Fried, CEO, Director, Stock Options, Employee Stock Options, Insider Transaction, Form 4, Executive Compensation, Equity Grant, Vesting